These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26462129)

  • 1. Chemotherapy: Limited use of the intraperitoneal route for ovarian cancer-why?
    Markman M
    Nat Rev Clin Oncol; 2015 Nov; 12(11):628-30. PubMed ID: 26462129
    [No Abstract]   [Full Text] [Related]  

  • 2. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 3. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.
    Markman M; Walker JL
    J Clin Oncol; 2006 Feb; 24(6):988-94. PubMed ID: 16461779
    [No Abstract]   [Full Text] [Related]  

  • 4. [Current topic of intraperitoneal infusions for treatment of ovarian cancer].
    Fujiwara K
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):224-227. PubMed ID: 18372511
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of intraperitoneal chemotherapy in the front-line setting.
    Markman M
    J Clin Oncol; 2003 May; 21(10 Suppl):145s-148s. PubMed ID: 12743130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.
    Elit L; Oliver TK; Covens A; Kwon J; Fung MF; Hirte HW; Oza AM
    Cancer; 2007 Feb; 109(4):692-702. PubMed ID: 17238181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understand the benefits and risks of intraperitoneal therapy for advanced ovarian cancer.
    Oestreicher P
    ONS Connect; 2007 Apr; 22(4):24-5. PubMed ID: 17477008
    [No Abstract]   [Full Text] [Related]  

  • 8. Simulation of Chemoperfusion Treatment for Abdominal Carcinomatosis.
    Bespalov VG; Belyaeva OA; Kireeva GS; Senchik KY; Stukov AN; Belyaev AM
    Bull Exp Biol Med; 2015 May; 159(1):81-4. PubMed ID: 26033596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
    Rowan K
    J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
    [No Abstract]   [Full Text] [Related]  

  • 10. What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?
    Markman M
    Int J Gynecol Cancer; 2008; 18 Suppl 1():36-9. PubMed ID: 18336398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of intraperitoneal chemotherapy in ovarian cancer.
    Markman M
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):809-10. PubMed ID: 17143249
    [No Abstract]   [Full Text] [Related]  

  • 12. Intraperitoneal chemotherapy for advanced epithelial ovarian cancer: many questions, much promise...
    Gaillard S; Armstrong D
    Oncology (Williston Park); 2011 Feb; 25(2):176, 178, 180. PubMed ID: 21456389
    [No Abstract]   [Full Text] [Related]  

  • 13. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
    Petignat P; du Bois A; Bruchim I; Fink D; Provencher DM
    Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can carboplatin replace cisplatin for intraperitoneal use?
    Fujiwara K
    Int J Gynecol Cancer; 2008; 18 Suppl 1():29-32. PubMed ID: 18336396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal chemotherapy: why the fuzz?
    Gotlieb WH
    Int J Gynecol Cancer; 2010 Oct; 20(11 Suppl 2):S14-6. PubMed ID: 21053524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point: Intraperitoneal chemotherapy in the management of ovarian cancer.
    Markman M
    J Natl Compr Canc Netw; 2004 Nov; 2(6):549-54. PubMed ID: 19780298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal treatment and dose-intense therapy in ovarian cancer.
    Ozols RF; Gore M; Tropé C; Grenman S
    Ann Oncol; 1999; 10 Suppl 1():59-64. PubMed ID: 10219455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
    Andreopoulou E; Chen T; Liebes L; Curtin J; Blank S; Wallach R; Hochster H; Muggia F
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):457-63. PubMed ID: 21069334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
    American College of Obstetricians and Gynecologists
    Obstet Gynecol; 2008 Jan; 111(1):249. PubMed ID: 18165421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intraperitoneal cisplatin chemotherapy for ovarian cancer].
    Hayashi H; Nishii H; Ueda K; Kunitou S; Wada S; Takanashi H; Kobayashi S; Yasuda M
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2043-8. PubMed ID: 11791382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.